fgd1 Resolved · high auto-curated

H37Rv Rv0407 · MTBC0 mtbc0_000427 · 336 aa · 494148–495158 MTBC0 (+) · RefSeq NP_214921.1

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)F420-dependent glucose-6-phosphate dehydrogenase
MTBC0 PGAP re-annotationglucose-6-phosphate dehydrogenase (coenzyme-F420)
Revised (this work)Glucose-6-phosphate dehydrogenase (coenzyme-F420). Pfam: Bac_luciferase (PF00296.27).
Functional category (TubercuList)intermediary metabolism and respiration

Curation note: 2026-08-26 (feedback from the group's own BPaL/BPaLM resistance-emergence manuscript, mtbc/bpal_resistance_emergence project; submission in preparation for the Journal of Antimicrobial Chemotherapy after a desk-reject by Antimicrobial Agents and Chemotherapy, not yet peer-reviewed). Pretomanid has no WHO catalogue entry and no public drug-susceptibility data, so resistance determinants were sought phenotype-free by phylogenetic convergence across a 132,609-strain MTBC pangenome. Position 210 surfaces as the headline candidate: uncatalogued at any grade, struck by five distinct residues on four independent lineage backgrounds, and structurally proximal to the F420 cofactor pocket. Position 10 is a second, lower-confidence convergent candidate. Both rest on structural and convergence evidence, not on genome-wide significance or DST. An emergence-profiling test (validated against catalogued drug-era ddn determinants) places both as standing polymorphisms -- present before the drugs, multi-clade, on non-MDR backgrounds -- rather than drug-era-selected, i.e. candidate priming variation. Full manuscript and code: https://github.com/cguyeux/deciphering-tuberculosis-with-ai/tree/main/bpal_resistance_emergence.

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 33 publications

33 TB publications mention this gene. 33 publications discuss this gene. Queried separately, 33 records carry a M. tuberculosis context and 3 a non-TB mycobacterial context (species named in the 3-record verified sample: M. smegmatis (3)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 33: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Resistance to Linezolid and Pretomanid in the Era of Modern Drug-Resistant Tuberculosis Treatment in South Africa: A Systematic Review and Meta-Analysis. doi:10.3390/antibiotics15060543 2026
Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review. doi:10.1002/hsr2.72481 2026
Delamanid or pretomanid for treatment of multidrug resistant tuberculosis---spoilt for choice? doi:10.1016/j.ijtb.2025.09.005 2026
Elucidating the structural basis of Fgd1-mediated resistance to Delamanid in Mycobacterium tuberculosis. doi:10.1016/j.jmgm.2026.109382 2026
Spontaneous mutations to delamanid and pretomanid resistance in Mycobacterium tuberculosis: SNPs confer high-level resistance. doi:10.1016/j.ijantimicag.2026.107789 2026
34 records returned by the alias sweep (a separate sweep from the 33 above; both are shown, neither is exhaustive)

Searched as: Rv0407, fgd1, Mb0415, ML0269c, MMAR_0709, MSMEG_0777, MAB_4230c — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
No phenotypic resistance observed for most group-3 and -4 variants in Mycobacterium tuberculosis genes related to bedaquiline, clofazimine, delamanid, and pretomanid in a Central and West African context. doi:10.1128/spectrum.02005-26 Microbiol Spectr 2026
Resistance to Linezolid and Pretomanid in the Era of Modern Drug-Resistant Tuberculosis Treatment in South Africa: A Systematic Review and Meta-Analysis. doi:10.3390/antibiotics15060543 Antibiotics (Basel) 2026
Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review. doi:10.1002/hsr2.72481 Health Sci Rep 2026
Delamanid or pretomanid for treatment of multidrug resistant tuberculosis---spoilt for choice? doi:10.1016/j.ijtb.2025.09.005 Indian J Tuberc 2026
Elucidating the structural basis of Fgd1-mediated resistance to Delamanid in Mycobacterium tuberculosis. doi:10.1016/j.jmgm.2026.109382 names it J Mol Graph Model 2026
Spontaneous mutations to delamanid and pretomanid resistance in Mycobacterium tuberculosis: SNPs confer high-level resistance. doi:10.1016/j.ijantimicag.2026.107789 Int J Antimicrob Agents 2026
Pretomanid for the treatment of drug resistant pulmonary tuberculosis: a comprehensive review. doi:10.1007/s00203-025-04508-8 Arch Microbiol 2025
Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran. doi:10.1186/s12866-025-04213-y BMC Microbiol 2025
Potential Role of Whole Genome Sequencing to Predict the Virulence, Anti-TB Resistance, and Variants of Mycobacterium tuberculosis Strains from Rifampicin-sensitive Pulmonary Tuberculosis Patients in Surabaya, East Java, Indonesia. doi:10.4103/ijmy.ijmy_54_25 Int J Mycobacteriol 2025
Computational structure-guided approach to simulate delamanid and pretomanid binding to mycobacterial F420 redox cycling proteins: identification of key determinants of resistance. doi:10.1080/07391102.2025.2498621 J Biomol Struct Dyn 2025
Expression and purification of Mycobacterium tuberculosis F(420)-dependent glucose-6-phosphate dehydrogenase enzyme using Escherichia coli. doi:10.1016/j.pep.2024.106650 Protein Expr Purif 2025
A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis. doi:10.1002/jcla.25091 J Clin Lab Anal 2024
Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis. doi:10.1016/j.nmni.2024.101437 New Microbes New Infect 2024
Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice. doi:10.1016/j.ijantimicag.2023.106953 Int J Antimicrob Agents 2023
Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis. doi:10.1099/mic.0.001288 Microbiology (Reading) 2023
Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis. doi:10.1128/aac.00531-22 Antimicrob Agents Chemother 2022
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. doi:10.1038/s41598-021-98862-4 Sci Rep 2021
Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains. doi:10.1128/JCM.01304-20 J Clin Microbiol 2020
Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients. doi:10.1128/AAC.00513-20 Antimicrob Agents Chemother 2020
Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro. doi:10.2147/IDR.S257145 Infect Drug Resist 2020
Delamanid Resistance: Update and Clinical Management. doi:10.1093/cid/ciaa755 Clin Infect Dis 2020
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. doi:10.1093/jac/dkaa136 J Antimicrob Chemother 2020
Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid. doi:10.3390/antibiotics9030133 Antibiotics (Basel) 2020
Detection of Mycobacterium tuberculosis RNA in bioaerosols from pulmonary tuberculosis patients. doi:10.1016/j.ijid.2019.06.006 Int J Infect Dis 2019
Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. doi:10.1016/j.tube.2017.12.006 Tuberculosis (Edinb) 2018
Discovery and characterization of an F(420)-dependent glucose-6-phosphate dehydrogenase (Rh-FGD1) from Rhodococcus jostii RHA1. doi:10.1007/s00253-016-8038-y names it Appl Microbiol Biotechnol 2017
Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system. doi:10.1093/jac/dkw044 J Antimicrob Chemother 2016
Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. doi:10.1128/AAC.00308-15 Antimicrob Agents Chemother 2015
Sequence Analysis of lip R: A Good Method for Molecular Epidemiology of Clinical Isolates of Mycobacterium tuberculosis. doi:10.1007/s00284-015-0856-0 Curr Microbiol 2015
Differential expression of immunogenic proteins on virulent Mycobacterium tuberculosis clinical isolates. doi:10.1155/2014/741309 Biomed Res Int 2014
Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. doi:10.1128/AAC.05500-11 names it Antimicrob Agents Chemother 2011
Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. doi:10.1074/jbc.M801854200 names it J Biol Chem 2008
Expression, purification and crystallization of native and selenomethionine labeled Mycobacterium tuberculosis FGD1 (Rv0407) using a Mycobacterium smegmatis expression system. doi:10.1016/j.pep.2007.01.014 names it Protein Expr Purif 2007
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. doi:10.1073/pnas.0508392103 Proc Natl Acad Sci U S A 2006

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

Genomic-neighbour overlap (structural caveat) co-directional · 1 % of gene

Neighbourpta (Rv0408, + strand)
Overlap8 bp, 1 % of this gene's length

co-directional overlap: ordinary (e.g. shared stop/start codons in an operon), not the Rv2438A-type artefact P20.1, derived from GFF3 gene coordinates, 2026-08-03.

CRISPRi vulnerability

Vulnerability index -1.21 (95% CI -6.48 to 5.33). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Caveat on this estimate. Bosch et al. flag this gene's vulnerability estimate as NOT certain, and here that call has a mechanical cause visible in the library itself: every guide targeting this gene is >=21 nt (str_span=0.273 on a 0-1 scale, near the genome floor), and guide repression strength saturates from 21 nt on -- so the library never sampled a partial knockdown for this gene, only the near-maximal repression plateau. The dose-response fit (and this VI) is therefore essentially unconstrained by data, not merely uncertain -- a limitation of the CRISPRi library design for the non-essential class (Bosch et al. 2021), not a defect in this specific measurement. n_guides=8 is descriptive only and does not predict this. Do not cite this VI as a standalone vulnerability claim.

Legacy record & comparison (Mycobrowser)

Mycobrowser functionCatalyzes oxidation of glucose-6-phosphate to 6-phosphogluconolactone using coenzyme F420 (an *-hydroxy-5-deazaflavin derivative) as the electron acceptor.
Mycobrowser EC 1.-.-.- · superseded EC numbering; the atlas uses the current class (1.1.98.2)

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb0415 · 99.7% identity
M. leprae ML0269c · 89.0% identity
M. marinum MMAR_0709 · 90.5% identity
M. smegmatis MSMEG_0777 · 89.3% identity
M. orygis RJtmp_000427 · 99.4% identity
M. abscessus MAB_4230c · 85.0% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt P9WNE1 SwissProt · reviewed · Evidence at protein level
UniProt nameF420-dependent glucose-6-phosphate dehydrogenase
EC (curated) EC 1.1.98.2
Curated functionCatalyzes the coenzyme F420-dependent oxidation of glucose 6-phosphate to 6-phosphogluconolactone. Appears to have a role in resistance to oxidative stress, via its consumption of G6P that serves as a source of reducing power to combat oxidative stress in mycobacteria. More precisely, is likely involved in a F420-dependent anti-oxidant mechanism that protects M.tuberculosis against oxidative stress and bactericidal agents..; FUNCTION: Is essential for the bioreductive activation of the bicyclic 4-nitroimidazole prodrug PA-824 (a nitroimidazo-oxazine) developed for anti-tuberculosis therapy aga.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category C Energy production and conversion
Preferred namefgd
eggNOG descriptionCatalyzes the coenzyme F420-dependent oxidation of glucose 6-phosphate (G6P) to 6-phosphogluconolactone. Appears to have a role in resistance to oxidative stress, via its consumption of G6P that serves as a source of reducing power to combat oxidative stress in mycobacteria
Orthologous groupCOG2141
EC number EC 1.1.98.2
KEGG orthology K15510
Gene Ontology (44) GO:0003674, GO:0003824, GO:0005488, GO:0005515, GO:0005575, GO:0005618, GO:0005622, GO:0005623, GO:0005737, GO:0005829, GO:0005886, GO:0008150 +32 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 0.656 · relaxed/neutral
Polymorphic sites (≥ 0.1% of strains) 3 synonymous, 6 missense, 0 nonsense, 0 frameshift

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Actinomycetia

M. canettii dN/dS (deep-divergence selection) 0.164 (low power) · 6 consensus substitution(s)
low power (6 canettii-consensus substitution(s)); present in M. canettii but dN/dS not reliable
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 53/53 (100%) · mean identity 90.2% · 4/4 closest MTBAP relatives
conserved across the genus (present in 53/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 6/13 non-Mycobacterium reference genomes (down to Actinomycetia) · mean identity 73.3%
detected across the class Actinomycetia (beyond Corynebacteriales) but not outside the phylum — an Actinobacteria-level ancient gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis)

DeJesus 2017 callNE · non-essential
What the call meansnon-essential
TA sites (Himar1) 20 in the ORF — 0 in the essential state, 0 growth-defect, 20 non-essential, 0 growth-advantage. Saturation 1.000, mean read count 101. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 20 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Mutant phenotypes (conditional Tn-seq, MtbTnDB) in-vivo phenotype

Conditionlog2FCqEffect
fitness after prolonged in vitro passage (in vitro passage) -3.960.0 required
altered fitness under 6 weeks hypoxia (stress) -2.910.0 required
differential fitness in a comparison whose nature could not be established (upstream metadata defect, see note) (undetermined) +2.370.0 disruption advantageous
fitness in mouse infection (in vivo) -2.100.0 required
fitness in mouse infection (in vivo) -1.910.006 required
fitness in mouse infection (in vivo) -1.880.024 required
fitness in mouse infection (in vivo) -1.860.012 required
fitness in mouse infection (in vivo) -1.580.021 required
fitness in mouse infection (in vivo) +1.140.016 disruption advantageous
altered fitness under 3 weeks hypoxia (stress) -1.040.0 required

Conditional fitness of transposon-disruption mutants across 10 significant condition(s) (|log2FC|≥1, q≤0.05), from the standardized MtbTnDB compendium. A negative log2FC means the mutant is depleted — the gene contributes to fitness in that condition. An in-vivo defect for a "hypothetical" is strong evidence it matters for infection, even without a known molecular function. Disruption (Tn insertion), not a clean deletion; genetic-interaction screens excluded.

Provenance note on a condition above. MtbTnDB labels this condition in vivo (Collaborative Cross mouse panel) and attributes it to Smith et al. 2022, eLife 74419. Both are wrong and for the same reason: its left arm, `mbio_H37Rv`, is the saturated H37Rv reference of DeJesus et al. 2017 (mBio 8(1):e02133-16, fourteen independent Tn libraries grown in standard medium), not a mouse strain, and the upstream generator read the token before `_vs_` as a mouse-strain name. The same sample is the in vitro control of six knockout screens in the same file. Measured here on rank correlation over 3971 genes: this condition tracks the other 81 first-order in vivo conditions at rho = +0.03, where those conditions track each other at +0.270 -- it does not behave like an infection measurement. What the comparison actually is could not be established, so it is reported as undetermined rather than renamed, and it is excluded from the in vivo count of this fiche.

Drug resistance (WHO catalogue) delamanid

delamanid113 catalogued resistance-associated variant(s)

This gene carries mutations classed Associated with resistance (WHO grade 1–2) in the consolidated catalogue (WHO 2nd ed. 2023 + tb-profiler). Only the R-associated tier is shown; "uncertain" and empirical-only signals are excluded. Test a specific strain or variant with the resistance tester. Research context, not a clinical diagnostic.

Proteomics (mass spectrometry) detected

MS detectiondetected in 12 of 16 independent MS datasets
Integrated abundance176.0 ppm · rank 912/3519 (74.1th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) no export signal, no TM helix

Predictionno signal peptide, no TM helix (DeepTMHMM class GLOB)
DeepTMHMM classGLOB

A verified absence of signals, which is not a compartment. No Sec/Tat signal peptide, no transmembrane helix and no lipobox were found on this sequence. The predictor reports topology and export signals; it does not measure where the protein ends up, so this page draws no cytoplasmic conclusion from it. In M. tuberculosis that reservation is not theoretical: the 12 Esx paralogues of this atlas — EsxA/ESAT-6 and EsxB/CFP-10 among them, the best-established secreted proteins of the species — carry this very call, because substrates of the type VII (ESX) secretion system leave no recognisable signal. « Secreted » and « no signal peptide » are true together here.

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length336 aa
Molecular weight37.0 kDa
Theoretical pI5.28
GRAVY-0.247 (hydrophilic)
Aliphatic index81.7
Aromaticity0.098
Instability index33.5 (stable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
Bac_luciferasePF00296.27 4.6e-6711–306 Luciferase-like monooxygenase

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 3c8n (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 2 solved

PDBMethodResolutionCoverage
3c8n X-ray diffraction 1.9 Å 100%
3b4y X-ray diffraction 1.95 Å 100%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (2 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 97.1

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
3c8n-assembly2_C 1.00 0.99 0.98 0.99 100% 98% / 100% 1.7e-61 sig 3c8n-assembly2_C Crystal structure of apo-FGD1 from Mycobacterium tuberculosis
3c8n-assembly2_D 1.00 0.99 0.97 0.99 99% 98% / 100% 1.1e-61 sig 3c8n-assembly2_D Crystal structure of apo-FGD1 from Mycobacterium tuberculosis
3c8n-assembly1_A 1.00 0.99 0.97 0.96 99% 98% / 96% 2.7e-61 sig 3c8n-assembly1_A Crystal structure of apo-FGD1 from Mycobacterium tuberculosis
3c8n-assembly1_B 1.00 0.98 0.97 0.98 99% 99% / 100% 8.8e-61 sig 3c8n-assembly1_B Crystal structure of apo-FGD1 from Mycobacterium tuberculosis
5lxe-assembly1_A 1.00 0.97 0.94 0.97 81% 98% / 99% 4.6e-51 sig 5lxe-assembly1_A F420-dependent glucose-6-phosphate dehydrogenase from Rhodococcus jostii RHA1

Foldseek search of the AlphaFold DB model (mean pLDDT 97.1, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Catalytic-site verification (M-CSA on the structural model) active site conserved

M-CSA entry532 · EC 1.1.98.5
Catalytic residues3/3 identical (3/3 aligned)
VerdictACTIVE-SITE CONSERVED (3/3 catalytic residues identical) -> likely active enzyme

Catalytic residues of the matched M-CSA reference enzyme mapped onto the structural model by alignment. An active-site-conserved verdict upgrades a mere fold match to a likely active enzyme; fold-only flags a shared fold whose catalytic machinery is not retained (a guard against over-calling).

Genomic context (neighbours & predicted operon) operon of 3

Upstream (5' on genome)Rv0406c (- strand, 77 bp gap)
Downstream (3' on genome)pta (+ strand, -8 bp gap)
Predicted operon fgd1 · pta · ackA

Neighbours from the H37Rv annotation (+ strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) no multi-gene operon predicted (singleton) — disagrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT0420) exponential phase: operon of 3, Rv0407 · Rv0408 · Rv0409 (coverage 19.42)
expressed, no multi-gene operon (stationary phase, coverage 20.05) — agrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Transcriptional regulation (signed TRN: ChIP-seq + TFOE)

Regulated by (2 TF) Rv1776c (represses) · Rv2034 (represses)

Regulatory edges from the ISB signed transcriptional regulatory network (TF ChIP-seq binding, Minch 2015 + TF-overexpression response, Rustad 2014). An edge is regulatory evidence (binding and/or expression change), not necessarily direct. For a "hypothetical", membership in a known regulon (e.g. DosR dormancy, PhoP virulence) is a physiological-context lead, not a function.

Condition: Condition-blind by construction. These edges come from transcription-factor OVEREXPRESSION in a single laboratory condition, so a listed regulator is not a claim that it governs this gene in every circumstance. Measured counter-examples exist within this atlas (see Rv2516c, where the DosR regulon collapses under moxifloxacin while the gene itself rises). Read a regulator as 'capable of shifting this gene', and look for the condition before building a hypothesis on it.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: pta (phosphate acetyltransferase), high confidence (score 889, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence).

Showing the 15 strongest of this gene's 34 partners at medium confidence (15 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 34 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv0408 pta phosphate acetyltransferase 903 889 ctx neighborhood:882
Rv0409 ackA acetate kinase 889 889 ctx neighborhood:882
Rv0406c beta lactamase-like protein 787 787 ctx neighborhood:784
Rv0044c oxidoreductase 804 777 ctx cooccurence:771
Rv3261 fbiA 2-phospho-L-lactate transferase 990 747 ctx cooccurence:728 textmining:965
Rv3547 ddn deazaflavin-dependent nitroreductase 983 745 ctx cooccurence:745 textmining:936
Rv3178 nitroreductase 953 745 ctx cooccurence:745 textmining:824
Rv1558 hypothetical protein 949 745 ctx cooccurence:745 textmining:812
Rv1261c hypothetical protein 845 741 ctx cooccurence:739 textmining:430
Rv2983 cofC 2-phospho-L-lactate guanylyltransferase 970 689 ctx cooccurence:677 textmining:909
Rv3262 fbiB coenzyme F420:L-glutamate ligase 988 685 ctx cooccurence:641 textmining:965
Rv2161c hypothetical protein 645 645 ctx cooccurence:641
Rv3093c oxidoreductase 604 604 ctx cooccurence:602
Rv3079c hypothetical protein 594 595 ctx cooccurence:585
Rv3072c hypothetical protein 591 568 ctx cooccurence:567

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: F420-dependent glucose-6-phosphate dehydrogenase
  • MTBC0 PGAP product: glucose-6-phosphate dehydrogenase (coenzyme-F420)
  • Pfam (hmmscan --cut_ga): Bac_luciferase PF00296.27 (E=5e-67)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_214921.1)
  • Domains: Pfam-A via hmmscan --cut_ga — Bac_luciferase (PF00296.27)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG2141
  • Curated reference: UniProt P9WNE1 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 97.1)
  • Catalytic-site verification: M-CSA (Ribeiro et al. 2018, doi:10.1093/nar/gkx1012), entry 532; catalytic residues aligned onto the structural model
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 34 functional partner(s); context anchor pta
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Transcriptional regulation: ISB signed TRN — TF ChIP-seq (Minch et al. 2015, doi:10.1038/ncomms6829) + TF overexpression (Rustad et al. 2014, doi:10.1186/gb-2014-15-11-502)
  • Mutant phenotypes: standardized Tn-seq compendium MtbTnDB (Jinich et al. 2025, doi:10.1111/mmi.15370), aggregating many primary Tn-seq studies across conditions
  • Drug resistance: consolidated catalogue, WHO 2nd ed. 2023 (9789240082410) + tb-profiler; only the resistance-associated tier (grade 1–2) is surfaced
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_000427|Rv0407|fgd1
MAELKLGYKASAEQFAPRELVELAVAAEAHGMDSATVSDHFQPWRHQGGHAPFSLSWMTAVGERTNRLLLGTSVLTPTFRYNPAVIAQAFATMGCLYPNRVFLGVGTGEALNEIATGYEGAWPEFKERFARLRESVGLMRQLWSGDRVDFDGDYYRLKGASIYDVPDGGVPVYIAAGGPAVAKYAGRAGDGFICTSGKGEELYTEKLMPAVREGAAAADRSVDGIDKMIEIKISYDPDPELALNNTRFWAPLSLTAEQKHSIDDPIEMEKAADALPIEQIAKRWIVASDPDEAVEKVGQYVTWGLNHLVFHAPGHDQRRFLELFQSDLAPRLRRLG